The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Biosimilars Treatment-Global Market Insights and Sales Trends 2024
Synopsis
The global Biosimilars Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Biosimilars Treatment in various end use industries. The expanding demands from the Oncology, Chronic and Autoimmune Disease, Blood Disorders and Growth Hormone Disease, are propelling Biosimilars Treatment market. Recombinant Non – Glycosylated Proteins, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Recombinant Glycosylated Proteins segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Biosimilars Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Biosimilars Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Biosimilars Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Biosimilars Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Biosimilars Treatment covered in this report include Bayer, Eli Lily, Inc., Pfizer, Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Limited, Amgen Inc., Biocon, Dr. Reddy’s Laboratories and Roche Ltd., etc.
The global Biosimilars Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bayer
Eli Lily, Inc.
Pfizer, Inc.
Sandoz International GmbH
Teva Pharmaceutical Industries Limited
Amgen Inc.
Biocon
Dr. Reddy’s Laboratories
Roche Ltd.
Celltrion, Inc.
Samsung Bioepis
Global Biosimilars Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Biosimilars Treatment market, Segment by Type:
Recombinant Non – Glycosylated Proteins
Recombinant Glycosylated Proteins
Recombinant Peptides
Global Biosimilars Treatment market, by Application
Oncology
Chronic and Autoimmune Disease
Blood Disorders
Growth Hormone Disease
Infectious Disease
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Biosimilars Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Biosimilars Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Biosimilars Treatment in various end use industries. The expanding demands from the Oncology, Chronic and Autoimmune Disease, Blood Disorders and Growth Hormone Disease, are propelling Biosimilars Treatment market. Recombinant Non – Glycosylated Proteins, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Recombinant Glycosylated Proteins segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Biosimilars Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Biosimilars Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Biosimilars Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Biosimilars Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Biosimilars Treatment covered in this report include Bayer, Eli Lily, Inc., Pfizer, Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Limited, Amgen Inc., Biocon, Dr. Reddy’s Laboratories and Roche Ltd., etc.
The global Biosimilars Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bayer
Eli Lily, Inc.
Pfizer, Inc.
Sandoz International GmbH
Teva Pharmaceutical Industries Limited
Amgen Inc.
Biocon
Dr. Reddy’s Laboratories
Roche Ltd.
Celltrion, Inc.
Samsung Bioepis
Global Biosimilars Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Biosimilars Treatment market, Segment by Type:
Recombinant Non – Glycosylated Proteins
Recombinant Glycosylated Proteins
Recombinant Peptides
Global Biosimilars Treatment market, by Application
Oncology
Chronic and Autoimmune Disease
Blood Disorders
Growth Hormone Disease
Infectious Disease
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Biosimilars Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Biosimilars Treatment
1.1 Biosimilars Treatment Market Overview
1.1.1 Biosimilars Treatment Product Scope
1.1.2 Biosimilars Treatment Market Status and Outlook
1.2 Global Biosimilars Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Biosimilars Treatment Market Size by Region (2018-2029)
1.4 Global Biosimilars Treatment Historic Market Size by Region (2018-2023)
1.5 Global Biosimilars Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Biosimilars Treatment Market Size (2018-2029)
1.6.1 North America Biosimilars Treatment Market Size (2018-2029)
1.6.2 Europe Biosimilars Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Biosimilars Treatment Market Size (2018-2029)
1.6.4 Latin America Biosimilars Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Biosimilars Treatment Market Size (2018-2029)
2 Biosimilars Treatment Market by Type
2.1 Introduction
2.1.1 Recombinant Non – Glycosylated Proteins
2.1.2 Recombinant Glycosylated Proteins
2.1.3 Recombinant Peptides
2.2 Global Biosimilars Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Biosimilars Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Biosimilars Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Biosimilars Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Biosimilars Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Biosimilars Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Biosimilars Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Biosimilars Treatment Revenue Breakdown by Type (2018-2029)
3 Biosimilars Treatment Market Overview by Application
3.1 Introduction
3.1.1 Oncology
3.1.2 Chronic and Autoimmune Disease
3.1.3 Blood Disorders
3.1.4 Growth Hormone Disease
3.1.5 Infectious Disease
3.2 Global Biosimilars Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Biosimilars Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global Biosimilars Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Biosimilars Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Biosimilars Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Biosimilars Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Biosimilars Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Biosimilars Treatment Revenue Breakdown by Application (2018-2029)
4 Biosimilars Treatment Competition Analysis by Players
4.1 Global Biosimilars Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Biosimilars Treatment as of 2022)
4.3 Date of Key Players Enter into Biosimilars Treatment Market
4.4 Global Top Players Biosimilars Treatment Headquarters and Area Served
4.5 Key Players Biosimilars Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Biosimilars Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Bayer
5.1.1 Bayer Profile
5.1.2 Bayer Main Business
5.1.3 Bayer Biosimilars Treatment Products, Services and Solutions
5.1.4 Bayer Biosimilars Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 Bayer Recent Developments
5.2 Eli Lily, Inc.
5.2.1 Eli Lily, Inc. Profile
5.2.2 Eli Lily, Inc. Main Business
5.2.3 Eli Lily, Inc. Biosimilars Treatment Products, Services and Solutions
5.2.4 Eli Lily, Inc. Biosimilars Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 Eli Lily, Inc. Recent Developments
5.3 Pfizer, Inc.
5.3.1 Pfizer, Inc. Profile
5.3.2 Pfizer, Inc. Main Business
5.3.3 Pfizer, Inc. Biosimilars Treatment Products, Services and Solutions
5.3.4 Pfizer, Inc. Biosimilars Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 Sandoz International GmbH Recent Developments
5.4 Sandoz International GmbH
5.4.1 Sandoz International GmbH Profile
5.4.2 Sandoz International GmbH Main Business
5.4.3 Sandoz International GmbH Biosimilars Treatment Products, Services and Solutions
5.4.4 Sandoz International GmbH Biosimilars Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 Sandoz International GmbH Recent Developments
5.5 Teva Pharmaceutical Industries Limited
5.5.1 Teva Pharmaceutical Industries Limited Profile
5.5.2 Teva Pharmaceutical Industries Limited Main Business
5.5.3 Teva Pharmaceutical Industries Limited Biosimilars Treatment Products, Services and Solutions
5.5.4 Teva Pharmaceutical Industries Limited Biosimilars Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 Teva Pharmaceutical Industries Limited Recent Developments
5.6 Amgen Inc.
5.6.1 Amgen Inc. Profile
5.6.2 Amgen Inc. Main Business
5.6.3 Amgen Inc. Biosimilars Treatment Products, Services and Solutions
5.6.4 Amgen Inc. Biosimilars Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 Amgen Inc. Recent Developments
5.7 Biocon
5.7.1 Biocon Profile
5.7.2 Biocon Main Business
5.7.3 Biocon Biosimilars Treatment Products, Services and Solutions
5.7.4 Biocon Biosimilars Treatment Revenue (US$ Million) & (2018-2023)
5.7.5 Biocon Recent Developments
5.8 Dr. Reddy’s Laboratories
5.8.1 Dr. Reddy’s Laboratories Profile
5.8.2 Dr. Reddy’s Laboratories Main Business
5.8.3 Dr. Reddy’s Laboratories Biosimilars Treatment Products, Services and Solutions
5.8.4 Dr. Reddy’s Laboratories Biosimilars Treatment Revenue (US$ Million) & (2018-2023)
5.8.5 Dr. Reddy’s Laboratories Recent Developments
5.9 Roche Ltd.
5.9.1 Roche Ltd. Profile
5.9.2 Roche Ltd. Main Business
5.9.3 Roche Ltd. Biosimilars Treatment Products, Services and Solutions
5.9.4 Roche Ltd. Biosimilars Treatment Revenue (US$ Million) & (2018-2023)
5.9.5 Roche Ltd. Recent Developments
5.10 Celltrion, Inc.
5.10.1 Celltrion, Inc. Profile
5.10.2 Celltrion, Inc. Main Business
5.10.3 Celltrion, Inc. Biosimilars Treatment Products, Services and Solutions
5.10.4 Celltrion, Inc. Biosimilars Treatment Revenue (US$ Million) & (2018-2023)
5.10.5 Celltrion, Inc. Recent Developments
5.11 Samsung Bioepis
5.11.1 Samsung Bioepis Profile
5.11.2 Samsung Bioepis Main Business
5.11.3 Samsung Bioepis Biosimilars Treatment Products, Services and Solutions
5.11.4 Samsung Bioepis Biosimilars Treatment Revenue (US$ Million) & (2018-2023)
5.11.5 Samsung Bioepis Recent Developments
6 North America
6.1 North America Biosimilars Treatment Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Biosimilars Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Biosimilars Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Biosimilars Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Biosimilars Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Biosimilars Treatment Market Dynamics
11.1 Biosimilars Treatment Industry Trends
11.2 Biosimilars Treatment Market Drivers
11.3 Biosimilars Treatment Market Challenges
11.4 Biosimilars Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
